Apoptosis induction in Jurkat cells and sCD95 levels in women's sera are related with the risk of developing cervical cancer

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Aguilar Lemarroy, Adriana ^a   Romero Ramos, Jose E ^a   Olimon Andalon, Vicente ^a   Hernandez Flores, Georgina ^a   Lerma Diaz, Jose M ^a   Ortiz Lazareno, Pablo C ^a   Morgan Villela, Gilberto ^a   del Toro Arreola, Susana ^b   Bravo Cuellar, Alejandro ^a   Jave Suarez, Luis F ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; LIPOCORTIN 5; PROPIDIUM IODIDE; TUMOR MARKER;

ADULT; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER RISK; CELL PROTECTION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL LINE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RISK ASSESSMENT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; AGED; BLOOD; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTION AND FORECASTING; RISK FACTOR; UTERINE CERVIX TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; APOPTOSIS; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; JURKAT CELLS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 42649112122     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-99     Document Type: Article

References (49)

1. Hanahan D Weinberg RA The hallmarks of cancer Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9 10647931
2. Debatin KM Krammer PH Death receptors in chemotherapy and cancer Oncogene 2004, 23:2950-2966. 10.1038/sj.onc.1207558 15077156
3. Fulda S Debatin KM Apoptosis signaling in tumor therapy Ann N Y Acad Sci 2004, 1028:150-156. 10.1196/annals.1322.016 15650241
4. Malaguarnera L Implications of apoptosis regulators in tumorigenesis Cancer Metastasis Rev 2004, 23:367-387. 10.1023/ B:CANC.0000031774.32572.df 15197336
5. Townson JL Naumov GN Chambers AF The role of apoptosis in tumor progression and metastasis Curr Mol Med 2003, 3:631-642. 10.2174/ 1566524033479483 14601637
6. Igney FH Krammer PH Immune escape of tumors: Apoptosis resistance and tumor counterattack J Leukoc Biol 2002, 71:907-920. 12050175
7. Lettini AA Guidoboni M Fonsatti E Anzalone L Cortini E Maio M Epigenetic remodelling of DNA in cancer Histol Histopathol 2007, 22:1413-1424. 17701921
8. French LE Tschopp J Defective death receptor signaling as a cause of tumor immune escape Semin Cancer Biol 2002, 12:51-55. 10.1006/ scbi.2001.0405 11926412
9. Lavrik I Golks A Krammer PH Death receptor signaling J Cell Sci 2005, 118:265-267. 10.1242/jcs.01610 15654015
10. Fas SC Fritzsching B Suri-Payer E Krammer PH Death receptor signaling and its function in the immune system Curr Dir Autoimmun 2006, 9:1-17. 16394652
11. Nagata S Fas ligand-induced apoptosis Annu Rev Genet 1999, 33:29-55. 10.1146/annurev.genet.33.1.29 10690403
12. Oehm A Behrmann I Falk W Pawlita M Maier G Klas C Li-Weber M Richards S Dhein J Trauth BC. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen J Biol Chem 1992, 267:10709-10715. 1375228
13. Itoh N Yonehara S Ishii A Yonehara M Mizushima S Sameshima M Hase A Seto Y Nagata S The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis Cell 1991, 66:233-243. 10.1016/ 0092-8674(91)90614-5 1713127
14. Chinnaiyan AM Tepper CG Seldin MF O'Rourke K Kischkel FC Hellbardt S Krammer PH Peter ME Dixit VM FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis J Biol Chem 1996, 271:4961-4965. 10.1074/jbc.271.9.4961 8617770
15. Kischkel FC Hellbardt S Behrmann I Germer M Pawlita M Krammer PH Peter ME Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor EMBO J 1995, 14:5579-5588. 394672 8521815
16. Kischkel FC Lawrence DA Tinel A LeBlanc H Virmani A Schow P Gazdar A Blenis J Arnott D Ashkenazi A Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8 J Biol Chem 2001, 276:46639-46646. 10.1074/jbc.M105102200 11583996
17. Cascino I Papoff G Eramo A Ruberti G Soluble Fas/Apo-1 splicing variants and apoptosis Front Biosci 1996, 1:d12-d18. 9159204
18. Ueno T Toi M Tominaga T Circulating soluble Fas concentration in breast cancer patients Clin Cancer Res 1999, 5:3529-3533. 10589768
19. Sheen-Chen SM Chen HS Eng HL Chen WJ Circulating soluble Fas in patients with breast cancer World J Surg 2003, 27:10-13. 10.1007/ s00268-002-6378-5 12557031
20. Mizutani Y Yoshida O Bonavida B Prognostic significance of soluble Fas in the serum of patients with bladder cancer J Urol 1998, 160:571-576. 10.1016/S0022-5347(01)62960-4 9679930
21. Nonomura N Nishimura K Ono Y Fukui T Harada Y Takaha N Takahara S Okuyama A Soluble Fas in serum from patients with renal cell carcinoma Urology 2000, 55:151-155. 10.1016/S0090-4295(99)00379-9 10654915
22. Peng Z Tang H Ling Y Han G Apoptosis and Fas system are significantly involved in the process of liver cirrhosis converting into hepatocellular carcinoma J Tongji Med Univ 2001, 21:126-9, 148. 11523216
23. Kondera-Anasz Z Mielczarek-Palacz A Sikora J Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors Apoptosis 2005, 10:1143-1149. 10.1007/s10495-005-1018-9 16151647
24. Konno R Takano T Sato S Yajima A Serum soluble fas level as a prognostic factor in patients with gynecological malignancies Clin Cancer Res 2000, 6:3576-3580. 10999747
25. Tanaka M Suda T Haze K Nakamura N Sato K Kimura F Motoyoshi K Mizuki M Tagawa S Ohga S Hatake K Drummond AH Nagata S Fas ligand in human serum Nat Med 1996, 2:317-322. 10.1038/nm0396-317 8612231
26. Midis GP Shen Y Owen-Schaub LB Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy Cancer Res 1996, 56:3870-3874. 8752148
27. Kato K Ohshima K Ishihara S Anzai K Suzumiya J Kikuchi M Elevated serum soluble Fas ligand in natural killer cell proliferative disorders Br J Haematol 1998, 103:1164-1166. 10.1046/j.1365-2141.1998.01095.x 9886336
28. Nagao M Nakajima Y Hisanaga M Kayagaki N Kanehiro H Aomatsu Y Ko S Yagita H Yamada T Okumura K Nakano H The alteration of Fas receptor and ligand system in hepatocellular carcinomas: How do hepatoma cells escape from the host immune surveillance in vivo? Hepatology 1999, 30:413-421. 10.1002/hep.510300237 10421649
29. Parkin DM Bray F Ferlay J Pisani P Global cancer statistics, 2002 CA Cancer J Clin 2005, 55:74-108. 15761078
30. Bosch FX de SS The epidemiology of human papillomavirus infection and cervical cancer Dis Markers 2007, 23:213-227. 17627057
31. zur HH Papillomaviruses and cancer: From basic studies to clinical application Nat Rev Cancer 2002, 2:342-350. 10.1038/nrc798 12044010
32. Walboomers JM Jacobs MV Manos MM Bosch FX Kummer JA Shah KV Snijders PJ Peto J Meijer CJ Munoz N Human papillomavirus is a necessary cause of invasive cervical cancer worldwide J Pathol 1999, 189:12-19. 10.1002/ (SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F 10451482
33. Wentzensen N von Knebel DM Biomarkers in cervical cancer screening Dis Markers 2007, 23:315-330. 17627065
34. Vinokurova S Wentzensen N von Knebel DM Analysis of p16INK4a and integrated HPV genomes as progression markers Methods Mol Med 2005, 119:73-83. 16350398
35. Syrjanen KJ Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated human papillomavirus (HPV) Eur J Obstet Gynecol Reprod Biol 1996, 65:45-53. 10.1016/0028-2243(95)02303-A 8706956
36. Holowaty P Miller AB Rohan T To T Natural history of dysplasia of the uterine cervix J Natl Cancer Inst 1999, 91:252-258. 10.1093/jnci/ 91.3.252 10037103
37. Peter ME Dhein J Ehret A Hellbardt S Walczak H Moldenhauer G Krammer PH APO-1 (CD95)-dependent and -independent antigen receptor-induced apoptosis in human T and B cell lines Int Immunol 1995, 7:1873-1877. 10.1093/intimm/7.11.1873 8580085
38. Kim JW Wieckowski E Taylor DD Reichert TE Watkins S Whiteside TL Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes Clin Cancer Res 2005, 11:1010-1020. 15709166
39. Vejda S Posovszky C Zelzer S Peter B Bayer E Gelbmann D Schulte-Hermann R Gerner C Plasma from cancer patients featuring a characteristic protein composition mediates protection against apoptosis Mol Cell Proteomics 2002, 1:387-393. 10.1074/mcp.M200004-MCP200 12118080
40. Gurova KV Gudkov AV Paradoxical role of apoptosis in tumor progression J Cell Biochem 2003, 88:128-137. 10.1002/jcb.10382 12461782
41. Krammer PH Kaminski M Kiessling M Gulow K No Life Without Death Adv Cancer Res 2007, 97C:111-138. 17419943
42. Cheng J Zhou T Liu C Shapiro JP Brauer MJ Kiefer MC Barr PJ Mountz JD Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule Science 1994, 263:1759-1762. 10.1126/science.7510905 7510905
43. Mouawad R Khayat D Soubrane C Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma Melanoma Res 2000, 10:461-467. 10.1097/ 00008390-200010000-00008 11095407
44. Jablonska E Kiersnowska-Rogowska B Rogowski F Parfienczyk A Puzewska W Bukin M Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL Rocz Akad Med Bialymst 2005, 50:204-207. 16358967
45. Sahin M Aydintug O Tunc SE Tutkak H Naziroglu M Serum soluble Fas levels in patients with autoimmune rheumatic diseases Clin Biochem 2007, 40:6-10. 10.1016/j.clinbiochem.2006.09.003 17056024
46. Kolomecki K Maciaszczyk P Stepien H Cywinski J Cielecka J Stepien T Kuzdak K [Evaluation of p53 and soluble Fas ligand (sFasL) serum level concentration as indicators of apoptosis in serum of patients with benign and malignant primary follicular thyroid tumors] Endokrynol Pol 2006, 57:320-325. 17006831
47. Lim SC Expression of Fas ligand and sFas ligand in human gastric adenocarcinomas Oncol Rep 2002, 9:103-107. 11748465
48. Osorio LM Guilar-Santelises M De SA Hachiya T Mellstedt H Jondal M Increased serum levels of soluble Fas in progressive B-CLL Eur J Haematol 2001, 66:342-346. 10.1034/j.1600-0609.2001.066005342.x 11422415
49. Tsutsumi S Kuwano H Shimura T Morinaga N Mochiki E Asao T Circulating soluble Fas ligand in patients with gastric carcinoma Cancer 2000, 89:2560-2564. 10.1002/ 1097-0142(20001215)89:12<2560::AID-CNCR7>3.0.CO;2-Q 11135216